Clinical trial

Effects of Combined Antiemetic Protocol For The Prevention Of Postoperative Nausea And Vomiting In Orthognathic Surgery: A Randomized Double Blinded Clinical Study

Name
ozgedoganay.001
Description
In an effort to prevent or treat consistently high rates of PONV following maxillofacial operations, several medications, techniques and multimodal protocols have been studied. In the present study, the investigators hypothesized that combining metoclopramide with granisetron will improve PONV incidence when compared with granisetrone alone.
Trial arms
Trial start
2020-04-14
Estimated PCD
2021-04-05
Trial end
2021-04-05
Status
Completed
Phase
Early phase I
Treatment
Intravenous drug
medications were applied intravenously to the groups 30 minutes before end of the procedure
Arms:
Granisetron and Metoclopramide group, Granisetron group
Size
66
Primary endpoint
Postoperative nausea and vomiting
fully awake and on the 1st, 2nd, 4th, 6th , 8th and 24th hours postoperatively
Eligibility criteria
Inclusion Criteria: * Undergoing orthognathic surgery * ASA I and II physical status * aged between 18 and 60 years * must be volunteer to take study drugs Exclusion Criteria: * Unable or unwilling to give informed consent * Underwent to genioplasty * Documented hypersensitivity to study drugs * Gastroesophageal reflux or hiatal hernia * Diabetes mellitus * Renal insufficiency * Pregnancy * Electrolyte imbalance * Neurological disease * Mental retardation * Prolonged QT interval.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'randomized double blinded clinical study', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 66, 'type': 'ACTUAL'}}
Updated at
2024-06-12

1 organization

1 product

3 indications

Indication
Postoperative